These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 35879192)

  • 1. The first Japanese biobank of patient-derived pediatric acute lymphoblastic leukemia xenograft models.
    Tanaka K; Kato I; Dobashi Y; Imai JI; Mikami T; Kubota H; Ueno H; Ito M; Ogawa S; Nakahata T; Takita J; Toyoda H; Ogawa C; Adachi S; Watanabe S; Goto H
    Cancer Sci; 2022 Nov; 113(11):3814-3825. PubMed ID: 35879192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo activity of the dual PI3Kδ and PI3Kγ inhibitor duvelisib against pediatric acute lymphoblastic leukemia xenografts.
    Randall J; Evans K; Watts B; Smith CM; Hughes K; Earley EJ; Erickson SW; Pachter JA; Teicher BA; Smith MA; Lock RB
    Pediatr Blood Cancer; 2023 Aug; 70(8):e30398. PubMed ID: 37140091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of a clofarabine-based drug combination regimen for the preclinical evaluation of pediatric acute lymphoblastic leukemia.
    Xie J; Span M; van Maarseveen E; Langenhorst J; Boddy AV; Sia KCS; Sutton R; Venn N; Punt AM; Tyrrell V; Haber M; Trahair T; Lau L; Marshall GM; Lock RB
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28133. PubMed ID: 31876116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment and characterization of a non-gestational choriocarcinoma patient-derived xenograft model.
    Oda Y; Niimi K; Yoshida K; Tamauchi S; Yokoi A; Yasui Y; Nishiko Y; Shibata M; Shimizu Y; Yoshihara M; Ikeda Y; Yoshikawa N; Nishino K; Yamamoto E; Kajiyama H
    BMC Cancer; 2023 Nov; 23(1):1103. PubMed ID: 37957624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts.
    Jones L; McCalmont H; Evans K; Mayoh C; Kurmasheva RT; Billups CA; Houghton PJ; Smith MA; Lock RB
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27765. PubMed ID: 31012549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models.
    Okada S; Vaeteewoottacharn K; Kariya R
    Cells; 2019 Aug; 8(8):. PubMed ID: 31412684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.
    Townsend EC; Murakami MA; Christodoulou A; Christie AL; Köster J; DeSouza TA; Morgan EA; Kallgren SP; Liu H; Wu SC; Plana O; Montero J; Stevenson KE; Rao P; Vadhi R; Andreeff M; Armand P; Ballen KK; Barzaghi-Rinaudo P; Cahill S; Clark RA; Cooke VG; Davids MS; DeAngelo DJ; Dorfman DM; Eaton H; Ebert BL; Etchin J; Firestone B; Fisher DC; Freedman AS; Galinsky IA; Gao H; Garcia JS; Garnache-Ottou F; Graubert TA; Gutierrez A; Halilovic E; Harris MH; Herbert ZT; Horwitz SM; Inghirami G; Intlekofer AM; Ito M; Izraeli S; Jacobsen ED; Jacobson CA; Jeay S; Jeremias I; Kelliher MA; Koch R; Konopleva M; Kopp N; Kornblau SM; Kung AL; Kupper TS; LeBoeuf NR; LaCasce AS; Lees E; Li LS; Look AT; Murakami M; Muschen M; Neuberg D; Ng SY; Odejide OO; Orkin SH; Paquette RR; Place AE; Roderick JE; Ryan JA; Sallan SE; Shoji B; Silverman LB; Soiffer RJ; Steensma DP; Stegmaier K; Stone RM; Tamburini J; Thorner AR; van Hummelen P; Wadleigh M; Wiesmann M; Weng AP; Wuerthner JU; Williams DA; Wollison BM; Lane AA; Letai A; Bertagnolli MM; Ritz J; Brown M; Long H; Aster JC; Shipp MA; Griffin JD; Weinstock DM
    Cancer Cell; 2016 Apr; 29(4):574-586. PubMed ID: 27070704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors.
    Marques Da Costa ME; Zaidi S; Scoazec JY; Droit R; Lim WC; Marchais A; Salmon J; Cherkaoui S; Morscher RJ; Laurent A; Malinge S; Mercher T; Tabone-Eglinger S; Goddard I; Pflumio F; Calvo J; Redini F; Entz-Werlé N; Soriano A; Villanueva A; Cairo S; Chastagner P; Moro M; Owens C; Casanova M; Hladun-Alvaro R; Berlanga P; Daudigeos-Dubus E; Dessen P; Zitvogel L; Lacroix L; Pierron G; Delattre O; Schleiermacher G; Surdez D; Geoerger B
    Commun Biol; 2023 Sep; 6(1):949. PubMed ID: 37723198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment and evaluation of retroperitoneal liposarcoma patient-derived xenograft models: an ideal model for preclinical study.
    Xu C; Yan L; An Q; Zhang S; Guan X; Wang Z; Lv A; Liu D; Liu F; Dong B; Zhao M; Tian X; Hao C
    Int J Med Sci; 2022; 19(8):1241-1253. PubMed ID: 35928724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A living biobank of matched pairs of patient-derived xenografts and organoids for cancer pharmacology.
    Xu X; Kumari R; Zhou J; Chen J; Mao B; Wang J; Zheng M; Tu X; An X; Chen X; Zhang L; Tian X; Wang H; Dong X; Bao Z; Guo S; Ouyang X; Shang L; Wang F; Yan X; Zhang R; Vries RGJ; Clevers H; Li QX
    PLoS One; 2023; 18(1):e0279821. PubMed ID: 36602988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.
    Szymanska B; Wilczynska-Kalak U; Kang MH; Liem NL; Carol H; Boehm I; Groepper D; Reynolds CP; Stewart CF; Lock RB
    PLoS One; 2012; 7(3):e33894. PubMed ID: 22479469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo activity of the second-generation proteasome inhibitor ixazomib against pediatric T-cell acute lymphoblastic leukemia xenografts.
    Randall J; Evans K; Watts B; Kosasih HJ; Smith CM; Earley EJ; Erickson SW; Jocoy EL; Bult CJ; Teicher BA; de Bock CE; Smith MA; Lock RB
    Exp Hematol; 2024 Apr; 132():104176. PubMed ID: 38320689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PDX models reflect the proteome landscape of pediatric acute lymphoblastic leukemia but divert in select pathways.
    Uzozie AC; Ergin EK; Rolf N; Tsui J; Lorentzian A; Weng SSH; Nierves L; Smith TG; Lim CJ; Maxwell CA; Reid GSD; Lange PF
    J Exp Clin Cancer Res; 2021 Mar; 40(1):96. PubMed ID: 33722259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Supporting clinical decision making in advanced melanoma by preclinical testing in personalized immune-humanized xenograft mouse models.
    Ny L; Rizzo LY; Belgrano V; Karlsson J; Jespersen H; Carstam L; Bagge RO; Nilsson LM; Nilsson JA
    Ann Oncol; 2020 Feb; 31(2):266-273. PubMed ID: 31959343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenvatinib inhibits the growth of gastric cancer patient-derived xenografts generated from a heterogeneous population.
    Karalis JD; Yoon LY; Hammer STG; Hong C; Zhu M; Nassour I; Ju MR; Xiao S; Castro-Dubon EC; Agrawal D; Suarez J; Reznik SI; Mansour JC; Polanco PM; Yopp AC; Zeh HJ; Hwang TH; Zhu H; Porembka MR; Wang SC
    J Transl Med; 2022 Mar; 20(1):116. PubMed ID: 35255940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute lymphoblastic leukemia and synergistically works with dasatinib.
    Morishita T; Hayakawa F; Sugimoto K; Iwase M; Yamamoto H; Hirano D; Kojima Y; Imoto N; Naoe T; Kiyoi H
    Oncotarget; 2016 Aug; 7(35):56241-56252. PubMed ID: 27494842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Examining treatment responses of diagnostic marrow in murine xenografts to predict relapse in children with acute lymphoblastic leukaemia.
    Alruwetei AM; Bendak K; Yadav BD; Carol H; Evans K; Mayoh C; Sutton R; Marshall GM; Lock RB
    Br J Cancer; 2020 Sep; 123(5):742-751. PubMed ID: 32536690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis.
    Lenk L; Baccelli I; Laqua A; Heymann J; Reimer C; Dietterle A; Winterberg D; Mary C; Corallo F; Taurelle J; Narbeburu E; Neyton S; Déramé M; Pengam S; Vogiatzi F; Bornhauser B; Bourquin JP; Raffel S; Dovhan V; Schüler T; Escherich G; den Boer ML; Boer JM; Wessels W; Peipp M; Alten J; Antić Ž; Bergmann AK; Schrappe M; Cario G; Brüggemann M; Poirier N; Schewe DM
    Blood; 2024 Jun; 143(26):2735-2748. PubMed ID: 38518105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance.
    Nowak D; Liem NL; Mossner M; Klaumünzer M; Papa RA; Nowak V; Jann JC; Akagi T; Kawamata N; Okamoto R; Thoennissen NH; Kato M; Sanada M; Hofmann WK; Ogawa S; Marshall GM; Lock RB; Koeffler HP
    Exp Hematol; 2015 Jan; 43(1):32-43.e1-35. PubMed ID: 25450514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment of a patient-derived xenograft model and cell line of malignant transformation of mature cystic teratoma of the ovary.
    Tamauchi S; Suzuki S; Xuboya C; Yoshihara M; Yoshida K; Ikeda Y; Yoshikawa N; Kajiyama H; Kikkawa F
    J Obstet Gynaecol Res; 2021 Feb; 47(2):713-719. PubMed ID: 33300248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.